GREAT NECK, N.Y.--(BUSINESS WIRE)--Neogenix Oncology announced today that the U.S. Patent and Trade Mark Office (USPTO) has issued a Notice of Allowance for a patent application related to its 16C3 antibody. Discovered and developed by Neogenix Oncology, this antibody appears to have anti-tumor activity for both pancreatic and colorectal tumors, and may have both therapeutic and diagnostic utility. The antibody may have activity in other tumors as well, which the company will explore at such time as it prepares a pre-IND package for FDA review and designs a clinical trial for the 16C3 antibody. This patent will cover the third antibody line held by the Company.
